Successful pharmaceutical-grade streptozotocin (STZ)-induced hyperglycemia in a conscious tethered baboon (Papio hamadryas) model.
J Med Primatol
; 44(4): 202-17, 2015 Aug.
Article
em En
| MEDLINE
| ID: mdl-26122701
ABSTRACT
BACKGROUND:
Non-human primate (NHP) diabetic models using chemical ablation of ß-cells with STZ have been achieved by several research groups. Chemotherapeutic STZ could lead to serious adverse events including nephrotoxicity, hepatotoxicity, and mortality.METHODS:
We implemented a comprehensive therapeutic strategy that included the tether system, permanent indwelling catheter implants, an aggressive hydration protocol, management for pain with IV nubain and anxiety with IV midazolam, moment-by-moment monitoring of glucose levels post-STZ administration, and continuous intravenous insulin therapy.RESULTS:
A triphasic response in blood glucose after STZ administration was fully characterized. A dangerous hypoglycemic phase was also detected in all baboons. Other significant findings were hyperglycemia associated with low levels of plasma leptin, insulin and C-peptide concentrations, hyperglucagonemia, and elevated non-esterified fatty acids (NEFA) concentrations.CONCLUSIONS:
We successfully induced frank diabetes by IV administering a single dose of pharmaceutical-grade STZ safely and without adverse events in conscious tethered baboons.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Papio hamadryas
/
Diabetes Mellitus Experimental
/
Modelos Animais de Doenças
Tipo de estudo:
Guideline
/
Prognostic_studies
Limite:
Animals
Idioma:
En
Revista:
J Med Primatol
Ano de publicação:
2015
Tipo de documento:
Article
País de afiliação:
Estados Unidos